MAOB and Parkinson disease: In the field of NDs, safinamide was approved in Europe in February 2015 and in the United States in March 2017 for the treatment of Parkinson's disease (PD), due to its MTD-profile that combines dopaminergic (MAO-B and dopamine reuptake inhibition) and non-dopaminergic properties (blockade of voltage-dependent Na+ and Ca2+ channels).6